Panelists provide their closing thoughts on the disease state and treatment landscape of multidrug-resistant HIV.
Ryan Haumschild, PharmD, MS, MBA: Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you. Dr Sension, what are your final thoughts for our viewers after this discussion?
Michael Sension, MD: Multidrug resistance is a very interesting discussion. Each person who’s facing multidrug-resistant virus in their body is different. Each person has to have a customized approach to successful management. There’s no treatment algorithm or formula for treating multidrug resistance, but it truly is the art of medicine interacting with real human life patient dynamics that will successfully lead to a positive outcome.
Ryan Haumschild, PharmD, MS, MBA: I love the individual view of treatment. You’ve definitely given us a lot to think about with that shared decision-making framework. Dr Lopes, [what are] your final thoughts for our audience?
Maria Lopes, MD, MS: It’s an exciting time as we have more treatment options for this very small population. We started with less than 1%, and now we have 3 treatment options. There’s still the backbone issue, so it’s incumbent to focus on shared decision-making but also support and adherence. It’s not about 1 drug, so how can we improve the value of these treatments and get successful outcomes?
Ryan Haumschild, PharmD, MS, MBA: [There are] lots of innovations in therapy, but [there’s] still more work to be done. Mr Driffin, I’ll give you the final thoughts.
Daniel Driffin, BS, MPH: The conversation must be centered on social determinants of health. We have to have those ongoing conversations to ensure that solutions are being provided. Solutions include support systems, housing, employment, and insurance access, but also to ensure that individuals living with HIV have a valuable role in being the healthiest they can be with their medical providers.
Ryan Haumschild, PharmD, MS, MBA: Thank you to my expert panel and our viewing audience. We hope you found this AJMC® Peer Exchange to be useful and informative.
Transcript edited for clarity.
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL
May 21st 2024A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
Patients With COPD, PRISm at Increased All-Cause, Cause-Specific Mortality Risk
May 20th 2024Patients with chronic obstructive pulmonary disease (COPD) and/or preserved ratio impaired spirometry (PRISm) have an increased risk of all-cause and cause-specific mortality, highlighting the need for better understanding of these conditions through increased spirometry data collection.
Read More